Clinical efficacy of hepatitis C antiviral therapy is judged by “response”: 1. Early virological response (EVR): refers to a negative qualitative serum HCV-RNA test (or quantitative test less than the minimum detection limit) at 12 weeks of treatment, or quantitative test reduced by 2 log levels (Log) or more. Those with early EVR are prone to SVR, while those without EVR are less likely to obtain SVR, so EVR can be used as a predictor of sustained virological response (SVR). 2.End of treatment virological response (ETVR): i.e., negative qualitative HCV RNA test at the end of treatment (or quantitative test less than the minimum detection limit). 3.SVR: Qualitative test negative for HCV-RNA (or quantitative test less than the minimum detection limit) at the end of treatment with at least 24 weeks of follow-up. 4.Non-responder (NR): Those who have never obtained EVR, ETVR and SVR. 5.Relapse: HCV-RNA is negative by qualitative test (or quantitative test is less than the minimum detection limit) at the end of treatment, but becomes positive again after stopping the drug. 6.In-treatment reversion: HCV-RNA load was reduced or turned negative during treatment, but HCV-RNA load increased or turned positive before stopping the drug. In addition, from the final regression consideration, in addition to viral indicators and liver function indicators, liver fibrosis indicators are quite important. Sometimes, although the HCV-RNA is not negative and the ALT is sometimes still increased, but after treatment, the course of cirrhosis is significantly delayed and liver cancer does not occur, the treatment should also be considered to be effective.